- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02606604
Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS (MSCycling)
September 27, 2019 updated by: Lori Hochman, Stony Brook University
Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking Performance and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study
This study will seek to determine the benefits that FES-LE cycling has over cycling alone on walking performance and quality of life in people with multiple sclerosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Functional Electrical Stimulation (FES) is a rehabilitation tool that stimulates nerves via electrical current, causing muscles to contract.
When FES is appled to leg muscles during stationary cycling the legs move in a fixed rhythmical pattern.
Previous studies have demonstrated that FES during cycling is a safe and effective exercise for individuals recovering from spinal cord injury or stroke, but few have applied this tool to a progressive disorder, such as multiple sclerosis (MS).
The aim of this study is to assess the immediate and short-term effect of an 8-week training program comparing FES lower extremity cycling to cycling without FES.
Twenty volunteers with MS will participate.
They will be randomly assigned to a training group.
This study examine the effects of training on quality of life, endurance, walking speed, and step quality.
Participants will sign an informed consent and complete a questionnaire that includes medical history and demographic data.
Before training, immediately after training finishes and one month after training, self-report questionnaires, timed walking tests will be completed.
During the walking tests, step quality and speed will be measured with a sensor that is worn on a belt
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook Univeristy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Medical Diagnosis of MS
- Patient-determined Disease Steps score between 3.0 and 6.0 inclusive
- Ability to attend training sessions 3 times per week for an 8-10 week period
- Passing a submaximal exercise test
- Adequate hip range of motion (at least 110 degrees)
- Adequate knee range of motion (10-90 degrees)
Exclusion Criteria:
- Cognitive deficits that would interfere in ability to sign consent and understand the procedures for the study.
- History or presence of other neurological pathologies that interfere with movement
- Received physical therapy within the last 4 weeks prior to the study
- History of an acute exacerbation of their MS symptoms within 4 weeks prior to the study
- Immunosuppressive or steroid therapy within the past 4 weeks
- Significant spasticity in the legs that interferes with the cycling motion
- History of congestive heart failure
- Coronary Artery Disease
- Uncontrolled Hypertension
- History of epilepsy or seizures
- Cardiac demand pacemaker or implanted defibrillator
- Unhealed fractures in the legs
- Pressure sores or open wounds on the legs
- Pregnant or trying to conceive
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FES Cycling
The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks.
Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
|
Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling.
Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
Other Names:
|
Active Comparator: Cycling Only
The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks.
Electrical stimulation will not be applied to any muscles.
Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
|
Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling.
Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Velocity: Timed Walking
Time Frame: Baseline
|
Gait velocity was reported in meters/second based on a 25 foot walk test called the Timed 25 foot Walk Test.
Faster gait speeds are better outcomes.
|
Baseline
|
Gait Velocity: Timed Walking
Time Frame: 4 weeks
|
Gait velocity was reported in meters/second based on a 25 foot walk test called the Timed 25 foot Walk Test.
Faster gait speeds are better outcomes.
|
4 weeks
|
Gait Velocity: Timed Walking
Time Frame: 8 weeks
|
Gait velocity was reported in meters/second based on a 25 foot walk test called the Timed 25 foot Walk Test.
Faster gait speeds are better outcomes.
|
8 weeks
|
Gait Velocity: Timed Walking
Time Frame: 12 weeks
|
Gait velocity was reported in meters/second based on a 25 foot walk test called the Timed 25 foot Walk Test.
Faster gait speeds are better outcomes.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-reported Fatigue Using Modified Fatigue Impact Scale
Time Frame: Baseline
|
The Modified Fatigue Impact Scale is a 21 item self-report questionnaire that takes 5-10 minutes to complete.
It uses a 5-point likert scale to rate the patient's perception of how Multiple Sclerosis related fatigue affects an individual's life on an everyday basis.
It contains three subscales that include: cognitive, physical, and psychosocial dimensions.
Scores on the subscales can be analyzed individually or as a summed score to give an overall fatigue score.
Higher scores indicate a greater impact of fatigue.
The minimum score is a 0 and the maximum score is 81.
|
Baseline
|
Self-reported Fatigue Using Modified Fatigue Impact Scale
Time Frame: 8 weeks
|
The Modified Fatigue Impact Scale is a 21 item self-report questionnaire that takes 5-10 minutes to complete.
It uses a 5-point likert scale to rate the patient's perception of how Multiple Sclerosis related fatigue affects an individual's life on an everyday basis.
It contains three subscales that include: cognitive, physical, and psychosocial dimensions.
Scores on the subscales can be analyzed individually or as a summed score to give an overall fatigue score.
Higher scores indicate a greater impact of fatigue.
The minimum score is a 0 and the maximum score is 81.
|
8 weeks
|
Self-reported Walking Using 12 Item Multiple Sclerosis Walking Scale
Time Frame: Baseline
|
The Multiple Sclerosis Walking Scale is a 12-item self-report questionnaire that takes approximately 10 minutes to complete and reflects a persons' perception of the impact that multiple sclerosis has on walking ability during the past 2 weeks.
Each of the items scored ranges from 1 to 5, in which higher scores indicate a greater impact of multiple sclerosis on their walking.
Scores on the 12 items are summed.
To transform to a 0-100 scale, the minimum score of 12 is subtracted from the sum; the result is divided by 48 and then multiplied by 100.
The lowest score is 0 and the highest score is 100.
Higher scores mean a worse outcome.
|
Baseline
|
Self-reported Walking Using 12 Item Multiple Sclerosis Walking Scale
Time Frame: 8 weeks
|
The Multiple Sclerosis Walking Scale is a 12-item self-report questionnaire that takes approximately 10 minutes to complete and reflects a persons' perception of the impact that multiple sclerosis has on walking ability during the past 2 weeks.
Each of the items scored ranges from 1 to 5, in which higher scores indicate a greater impact of multiple sclerosis on their walking.
Scores on the 12 items are summed.
To transform to a 0-100 scale, the minimum score of 12 is subtracted from the sum; the result is divided by 48 and then multiplied by 100.
The lowest score is 0 and the highest score is 100.
Higher scores mean a worse outcome.
|
8 weeks
|
Overall Self-reported Quality of Life Using Multiple Sclerosis Quality of Life- 54
Time Frame: Baseline
|
The Multiple Sclerosis Quality of Life-54 is a self-report quality of life questionnaire.
It measures health-related quality of life using both generic and disease-specific measures and was constructed by experts in the field.
There is no overall score for this scale since it contains 12 subscales, two summary scores, and two single-item measures.
The quality of life subscale was the chosen outcome measure reported below.
The scores range from 0-100.
Higher scores on the scale notes improved outcome.
|
Baseline
|
Overall Self-reported Quality of Life Using Multiple Sclerosis Quality of Life- 54
Time Frame: 8 weeks
|
The Multiple Sclerosis Quality of Life-54 is a self-report quality of life questionnaire.
It measures health-related quality of life using both generic and disease-specific measures and was constructed by experts in the field.
There is no overall score for this scale since it contains 12 subscales, two summary scores, and two single-item measures.
The quality of life subscale was the chosen outcome measure reported below.
The scores range from 0-100.
Higher scores on the scale notes improved outcome.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lori I Hochman, PT, PhD, Stony Brook University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
March 19, 2015
First Submitted That Met QC Criteria
November 14, 2015
First Posted (Estimate)
November 17, 2015
Study Record Updates
Last Update Posted (Actual)
September 30, 2019
Last Update Submitted That Met QC Criteria
September 27, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 534378-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on RT 300: Lower Extremity Cycling
-
Children's Specialized HospitalUniversity of Medicine and Dentistry of New JerseyCompletedSpinal Cord Injury
-
University of LiverpoolCompleted
-
Chinese University of Hong KongUnknown
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeCompleted
-
University Medical Center GroningenNational Institute for Public Health and the Environment (RIVM); Isala; Innofeet and other collaboratorsActive, not recruitingDiabetes Mellitus | Lower Extremity AmputationsNetherlands
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeRecruitingCompartment Syndromes | Compartment Syndrome of Forearm | Compartment Syndrome of Lower LegUnited States
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeRecruiting
-
Hospital Angeles del PedregalCompletedLymphedema, Secondary | Lymphedema of Leg | Granuloma, Foreign-BodyMexico
-
Parker UniversityUniversity of Miami; University of Houston; Whittier UniversityCompleted
-
Medipol UniversityRecruitingEvaluation of Functionality of Amputees According to the Medicare Functional K Classification SystemAmputation | Amputation; Traumatic, Leg, LowerTurkey